357 related articles for article (PubMed ID: 9779699)
1. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.
Lundin J; Osterborg A; Brittinger G; Crowther D; Dombret H; Engert A; Epenetos A; Gisselbrecht C; Huhn D; Jaeger U; Thomas J; Marcus R; Nissen N; Poynton C; Rankin E; Stahel R; Uppenkamp M; Willemze R; Mellstedt H
J Clin Oncol; 1998 Oct; 16(10):3257-63. PubMed ID: 9779699
[TBL] [Abstract][Full Text] [Related]
2. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.
Osterborg A; Dyer MJ; Bunjes D; Pangalis GA; Bastion Y; Catovsky D; Mellstedt H
J Clin Oncol; 1997 Apr; 15(4):1567-74. PubMed ID: 9193354
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study.
Uppenkamp M; Engert A; Diehl V; Bunjes D; Huhn D; Brittinger G
Ann Hematol; 2002 Jan; 81(1):26-32. PubMed ID: 11807632
[TBL] [Abstract][Full Text] [Related]
4. Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders.
Pangalis GA; Dimopoulou MN; Angelopoulou MK; Tsekouras C; Vassilakopoulos TP; Vaiopoulos G; Siakantaris MP
Med Oncol; 2001; 18(2):99-107. PubMed ID: 11778765
[TBL] [Abstract][Full Text] [Related]
5. A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma.
Khorana A; Bunn P; McLaughlin P; Vose J; Stewart C; Czuczman MS
Leuk Lymphoma; 2001 Mar; 41(1-2):77-87. PubMed ID: 11342359
[TBL] [Abstract][Full Text] [Related]
6. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.
Pawson R; Dyer MJ; Barge R; Matutes E; Thornton PD; Emmett E; Kluin-Nelemans JC; Fibbe WE; Willemze R; Catovsky D
J Clin Oncol; 1997 Jul; 15(7):2667-72. PubMed ID: 9215839
[TBL] [Abstract][Full Text] [Related]
7. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.
Keating MJ; Cazin B; Coutré S; Birhiray R; Kovacsovics T; Langer W; Leber B; Maughan T; Rai K; Tjønnfjord G; Bekradda M; Itzhaki M; Hérait P
J Clin Oncol; 2002 Jan; 20(1):205-13. PubMed ID: 11773171
[TBL] [Abstract][Full Text] [Related]
8. Mycosis fungoides/Sézary syndrome: a report of three cases treated with Campath-1H as salvage treatment.
Capalbo S; Delia M; Dargenio M; Liso A; Diomede D; Garofalo L; Liso V
Med Oncol; 2003; 20(4):389-96. PubMed ID: 14716037
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia--change of regimen needed?
Rieger K; Von Grünhagen U; Fietz T; Thiel E; Knauf W
Leuk Lymphoma; 2004 Feb; 45(2):345-9. PubMed ID: 15101722
[TBL] [Abstract][Full Text] [Related]
10. [Campath-1H--a monoclonal antibody for treatment of non-Hodgkin's and chronic lymphatic leukemia].
de Nully Brown P; Hansen MM; Nissen NI
Ugeskr Laeger; 1997 Jul; 159(28):4389-93. PubMed ID: 9235735
[TBL] [Abstract][Full Text] [Related]
11. Antibody-based therapy of non-Hodgkin's lymphoma.
Foran JM
Best Pract Res Clin Haematol; 2002 Sep; 15(3):449-65. PubMed ID: 12468399
[TBL] [Abstract][Full Text] [Related]
12. Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52).
Osterborg A; Werner A; Halapi E; Lundin J; Harmenberg U; Wigzell H; Mellstedt H
Eur J Haematol; 1997 Jan; 58(1):5-13. PubMed ID: 9020367
[TBL] [Abstract][Full Text] [Related]
13. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.
Piro LD; White CA; Grillo-López AJ; Janakiraman N; Saven A; Beck TM; Varns C; Shuey S; Czuczman M; Lynch JW; Kolitz JE; Jain V
Ann Oncol; 1999 Jun; 10(6):655-61. PubMed ID: 10442187
[TBL] [Abstract][Full Text] [Related]
14. Alemtuzumab therapy in B-cell lymphoproliferative disorders.
Moreton P; Hillmen P
Semin Oncol; 2003 Aug; 30(4):493-501. PubMed ID: 12939718
[TBL] [Abstract][Full Text] [Related]
15. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.
Dearden CE; Matutes E; Cazin B; Tjønnfjord GE; Parreira A; Nomdedeu B; Leoni P; Clark FJ; Radia D; Rassam SM; Roques T; Ketterer N; Brito-Babapulle V; Dyer MJ; Catovsky D
Blood; 2001 Sep; 98(6):1721-6. PubMed ID: 11535503
[TBL] [Abstract][Full Text] [Related]
16. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.
Maloney DG; Grillo-López AJ; Bodkin DJ; White CA; Liles TM; Royston I; Varns C; Rosenberg J; Levy R
J Clin Oncol; 1997 Oct; 15(10):3266-74. PubMed ID: 9336364
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report.
Angiolillo AL; Yu AL; Reaman G; Ingle AM; Secola R; Adamson PC
Pediatr Blood Cancer; 2009 Dec; 53(6):978-83. PubMed ID: 19637330
[TBL] [Abstract][Full Text] [Related]
18. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
[TBL] [Abstract][Full Text] [Related]
19. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
Bremer K
J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
[TBL] [Abstract][Full Text] [Related]
20. Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H.
Lockwood CM; Hale G; Waldman H; Jayne DR
Rheumatology (Oxford); 2003 Dec; 42(12):1539-44. PubMed ID: 12949252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
